Mellow Hope completes clinical trial of H1N1 vaccine, receives approval from SFDA

HTDS www.htdsmedical.com The Company is pleased to provide the following update to its shareholders and followers on the (H1N1) Vaccine for Mellow Hope Inc, its China based subsidiary and other general business matters.

At the beginning of September, Mellow Hope completed the clinical trial of Influenza A (H1N1) Vaccine (Split Virion). The company received the clinical approval from the State Food and Drug Administration (SFDA) http://eng.sfda.gov.cn/eng. Production will be started shortly.

Mr. Terry Yuan CEO of HTDS said (sic) "Mellow Hope has received many inquiries from different countries, asking about the supply of this vaccine. The company is currently in overdrive preparing all the relevant documents to obtain the approval in all of these regions, from various jurisdictional authorities. We are very confident and expect that several significant deals will be finalized by the middle of October, or early November. We remind our shareholders that we beat out a lot of our competitors with our tenders, and we note that some are out in full force planting doubt about our business activities to our novice and unsuspecting shareholders."

Mr. Yuan exclaimed "Our business is doing fantastic! I can't say that any clearer or louder. Our revenues will spike in this 3rd or 4th quarter and once the numbers are released our shareholders will have plenty to smile about. Our audit has commenced, with our aspirations to become an OTCBB Company. I know that our North American office and our representatives there are busy providing the auditors data they require. Few weeks ago when we set the target of our share price of 3 cents per share we did so confidently. Now, with our H1N1 done and completed, HTDS en route to getting its audits completed, OTCBB listed, the cancer and anti aging project's of Slavica Bio Chem, actions we are taking against the naked shorting that has affected our stock, plus the sizable outstanding share reduction; in all fairness a 5 cent target is not an unreasonable or unrealistic target for HTDS."

On that note, Slavica Bio Chem is pleased to provide a video stream of its work. The web stream and English translations are available on www.htdsmedical.com under the section "Company News" The video is split in 3 segments. Permission was obtained from RTS TV for non commercial and informative use and to be placed on HTDS website.

Dr. Sanja Pekovic, Chief Project Scientist and Chief Strategy Officer summarized as following: "A few years ago Serbian government TV did a feature about our work, and it took a great public attention. It was about Multiple sclerosis, current therapies, there were also some patients, and our whole team. In the video Dr. Sanja Pekovic, Chief Project Scientist and Chief Strategy Officer and Prof Dr. Mirjana Stojiljkovic, Slavica Bio Chme's Medical Advisor can be seen and viewed in the TV documentary. Special thanks go out to Professor Rakic (See Biography Link) (http://www.sanu.ac.rs/English/Clanstvo/Biografije/LjubisavRakic.pdf ). Professor Rakic was pivotal in making Slavica Bio Chem a reality a project that began in 2005 and has expanded to encompass cancer research and anti aging projects.

In other company news, the company through its IR Company retained a former economic crimes prosecutor to investigate trading of its security, and its belief that its security is subject to naked shorting. Mr. Essman is an International business attorney and former Assistant State Attorney of Hillsborough County (Tampa), Florida, where he served with the Special Prosecutions Unit for Economic and White Collar Crimes. His has offices in Tarpon Springs and St. Petersburg, Florida.

The issuer's shareholders and followers can expect updates on these matters shortly as the Company is adamant to get to the bottom of that topic and has instructed its barrister to vigorously pursue the matter.